Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALCAFTADINE vs CHILDREN'S ALAWAY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective histamine H1 receptor antagonist; inhibits histamine release from mast cells and reduces ocular itch associated with allergic conjunctivitis.
Competitive antagonist of H1 histamine receptors, inhibiting histamine-mediated allergic responses; also blocks muscarinic acetylcholine receptors, contributing to anticholinergic effects.
FDA: Prevention of itching associated with allergic conjunctivitis,Off-label: No established off-label uses
Temporary relief of symptoms due to hay fever or other upper respiratory allergies,Temporary relief of runny nose, sneezing, itching of nose or throat, itchy, watery eyes due to hay fever
1 drop of 0.25% ophthalmic solution in each affected eye twice daily.
Children's Alaway (ketotifen fumarate ophthalmic solution) is approved for children aged 3 years and older. The typical dose is 1 drop in the affected eye(s) twice daily, approximately every 8-12 hours. There is no standard adult dose as the product is indicated only for pediatric use.
Terminal elimination half-life is approximately 2 hours (range 1.5–3 h) after topical ocular administration, appropriate for twice-daily dosing.
Terminal elimination half-life 2.5–3.5 hours in children; prolonged in renal impairment or neonates.
Not extensively metabolized; primarily excreted unchanged in urine. Cytochrome P450 metabolism is minimal.
Hepatic metabolism via CYP3A4, CYP2D6, and other pathways; also undergoes N-demethylation and hydroxylation.
Primarily renal (approximately 50% unchanged), with the remainder as metabolites; negligible biliary/fecal elimination.
Primarily renal (approx. 90%) as unchanged drug and glucuronide conjugates; minimal biliary/fecal elimination (<5%).
Approximately 40% bound to plasma proteins.
85–90% bound to albumin.
Vd is approximately 1.4 L/kg, indicating distribution beyond plasma into extravascular tissues.
0.8–1.0 L/kg; distributes widely into tissues including CNS.
Systemic bioavailability after topical ocular administration is low (estimated < 0.5%) due to dilution, local metabolism, and limited corneal penetration.
Oral: 85–95%; Rectal: 80–90%.
No dose adjustment required for any degree of renal impairment.
No dosage adjustment required for renal impairment. Ketotifen is minimally absorbed systemically after ophthalmic administration.
No dose adjustment required for any degree of hepatic impairment.
No dosage adjustment required for hepatic impairment. Systemic absorption is negligible.
Children 2 years and older: same as adult dose. Safety and efficacy in children under 2 years not established.
Children 3 years and older: 1 drop in the affected eye(s) twice daily. For children under 3 years, safety and efficacy not established.
No specific dose adjustment needed; use same dose as for younger adults.
No specific geriatric dosing information provided. Use same dosing as for younger adults; however, elderly patients may be more sensitive to anticholinergic effects, though systemic absorption is low.
None
None
Do not inject; for topical ophthalmic use only,Avoid wearing contact lenses if eyes are red,May cause temporary blurred vision after instillation,Use with caution in patients with known hypersensitivity
May cause drowsiness; avoid driving or operating machinery,Avoid use with other CNS depressants including alcohol,Use caution in patients with asthma, COPD, increased intraocular pressure, prostatic hyperplasia, or urinary retention,Do not exceed recommended dosage,Not for use in children under 2 years of age unless directed by a doctor,Do not use with MAO inhibitors
Hypersensitivity to alcaftadine or any component of the formulation
Hypersensitivity to any component of the formulation,Neonates or premature infants,Narrow-angle glaucoma,Bladder neck obstruction or symptomatic prostatic hypertrophy,During an asthma attack,Concomitant use with MAO inhibitors,Lactation (due to risk of infant sedation and anticholinergic effects)
No specific food interactions reported. As an ophthalmic preparation, systemic absorption is minimal and unlikely to be affected by food.
No clinically significant food interactions. No dietary restrictions required.
Alcaftadine is classified as Pregnancy Category B. Animal studies have not demonstrated teratogenic effects at doses up to 2400 times the human ocular dose. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, alcaftadine should be used during pregnancy only if clearly needed.
CHILDREN'S ALAWAY (diphenhydramine) is an antihistamine. In animal studies, no teratogenic effects at doses up to 5 times the human dose. Adequate human studies are lacking. First trimester: cautious use; some data suggest possible association with cleft palate. Second and third trimesters: generally considered low risk, but may cause uterine contractions or neonatal irritability near term.
It is not known whether alcaftadine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when alcaftadine is administered to a nursing woman. The M/P ratio has not been established.
Diphenhydramine is excreted in breast milk in small amounts. M/P ratio not well defined. The AAP considers it compatible with breastfeeding, but may cause drowsiness in infants. Caution in preterm or neonates.
No pharmacokinetic studies have been performed in pregnant women. Based on the available animal data and the low systemic exposure after ocular administration, no dosing adjustment is recommended during pregnancy.
No specific dose adjustment required in pregnancy. Use lowest effective dose and short duration. Pharmacokinetic changes may include increased volume of distribution and clearance in pregnancy, but clinical significance uncertain.
ALCAFTADINE is a topical ophthalmic antihistamine and mast cell stabilizer used for allergic conjunctivitis. Administer one drop twice daily in each affected eye. Onset of action is within minutes. Contraindicated in patients with hypersensitivity to any component. Use with caution in contact lens wearers; remove lenses before instillation and wait 10 minutes before reinserting. Do not touch dropper tip to any surface to avoid contamination.
Children's Alaway (ketotifen fumarate ophthalmic solution 0.025%) is a mast cell stabilizer and antihistamine indicated for prophylaxis and treatment of allergic conjunctivitis. Onset of symptom relief typically within minutes. For maximal prophylactic effect, initiate treatment prior to allergen exposure. Do not administer while wearing contact lenses; remove lenses before use and wait at least 10 minutes before reinserting. Preservative benzalkonium chloride may be absorbed by soft contact lenses. Each vial contains no preservative; discard after single use if using unit-dose vials. May cause transient stinging or burning upon instillation. Efficacy may be reduced if patient is also using ocular corticosteroids concurrently.
Do not wear contact lenses if your eyes are red; after the redness subsides, wait at least 10 minutes after instilling the drop before reinserting lenses.,Do not touch the dropper tip to your eye or any surface to avoid contamination.,Wait at least 5 minutes between using this drug and other eye drops.,If you miss a dose, use it as soon as you remember; if it is almost time for the next dose, skip the missed dose and resume your regular schedule.,Do not use more than prescribed; overuse may cause eye irritation.,Tell your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Wash hands before and after use.
Wash hands before use.,Tilt head back, pull down lower eyelid, and instill one drop into the affected eye(s).,Avoid touching the dropper tip to any surface to prevent contamination.,Close eye gently and press finger to the inner corner of the eye for 1-2 minutes to reduce systemic absorption.,Do not use while wearing contact lenses; remove lenses before use and wait at least 10 minutes before reinserting.,Mild temporary stinging or burning may occur upon instillation.,If symptoms worsen or persist more than 72 hours, consult your healthcare provider.,Store at room temperature away from moisture and heat.,Discard any unused solution 1 month after opening the bottle (multidose) or immediately after use (unit-dose vials).,Keep out of reach of children.
"Dextroamphetamine, a central nervous system stimulant, may reduce the sedative effects of Alcaftadine, an antihistamine used for allergic conjunctivitis, by opposing its central histamine H1 receptor blockade. This pharmacodynamic antagonism can lead to diminished sedation and potentially decreased therapeutic efficacy of Alcaftadine for its intended ocular antiallergic effects. Patients may experience reduced symptom relief and increased ocular discomfort."
"Hydroxyamphetamine may decrease the sedative activities of Alcaftadine."
"Phentermine may decrease the sedative activities of Alcaftadine."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALCAFTADINE vs CHILDREN'S ALAWAY, answered by our medical review team.
ALCAFTADINE is a Ophthalmic Antihistamine that works by Selective histamine H1 receptor antagonist; inhibits histamine release from mast cells and reduces ocular itch associated with allergic conjunctivitis.. CHILDREN'S ALAWAY is a Ophthalmic Antihistamine that works by Competitive antagonist of H1 histamine receptors, inhibiting histamine-mediated allergic responses; also blocks muscarinic acetylcholine receptors, contributing to anticholinergic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALCAFTADINE and CHILDREN'S ALAWAY depend on the specific clinical indication. These are both Ophthalmic Antihistamine agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALCAFTADINE is: 1 drop of 0.25% ophthalmic solution in each affected eye twice daily.. The standard adult dose of CHILDREN'S ALAWAY is: Children's Alaway (ketotifen fumarate ophthalmic solution) is approved for children aged 3 years and older. The typical dose is 1 drop in the affected eye(s) twice daily, approximately every 8-12 hours. There is no standard adult dose as the product is indicated only for pediatric use.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALCAFTADINE and CHILDREN'S ALAWAY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALCAFTADINE is classified as Category C. Alcaftadine is classified as Pregnancy Category B. Animal studies have not demonstrated teratogenic effects at doses up to 2400 times the human ocular dose. There are no adequate a. CHILDREN'S ALAWAY is classified as Category C. CHILDREN'S ALAWAY (diphenhydramine) is an antihistamine. In animal studies, no teratogenic effects at doses up to 5 times the human dose. Adequate human studies are lacking. First . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.